Safety evaluation of monophosphoryl lipid A (MPL): An immunostimulatory adjuvant

Regulatory Toxicology and Pharmacology

Volumn 35, Issue 3, 2002, Pages 398-413

  Baldrick, Paul ^a   Richardson, Derek ^b   Elliott, Gary ^c   Wheeler, Alan W ^b  

^a UK   (United Kingdom)

^b Allergy Therapeutics Ltd   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Adjuvant; Allergy vaccines; Immunostimulatory; MPL; Toxicity assessment

Indexed keywords

ALCOHOL; BACTERIUM LIPOPOLYSACCHARIDE; IMMUNOLOGICAL ADJUVANT; PHOSPHORYL LIPID A; PROPYLENE GLYCOL; TRIETHANOLAMINE; VACCINE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHROMOSOME ABERRATION; CONTROLLED STUDY; DOG; EMBRYO; FEMALE; FETUS; GENOTOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNE SYSTEM; LEUKOCYTE; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; SAFETY; SPLEEN; TOXICITY;

ANIMALIA; BACTERIA (MICROORGANISMS); CANIS FAMILIARIS; ORYCTOLAGUS CUNICULUS;

EID: 0036592999     PISSN: 02732300     EISSN: None     Source Type: Journal    
DOI: 10.1006/rtph.2002.1541     Document Type: Article

References (50)

1. Lipopolysaccharide, lipid A and liposomes containing lipid A as immunologic adjuvants
2. Inactivation of suppressor T-cell activity by nontoxic monophosphoryl lipid A
3. Ability of monophosphoryl lipid A to augment the antibody response of young mice
4. Pharmaceutical excipient development: The need for preclinical guidance
5. Effective adjuvants for the induction of antigen-specific delayed-type hypersensitivity
6. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration
7. Application of immunologic methods in clinical trials
8. Effect of monophosphoryl lipid A on the in vitro function of peritoneal leukocytes from uremic patients on continuous ambulatory peritoneal dialysis
9. Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen
10. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: Synthesis, characterization and immunogenicity
11. Preclinical and clinical experience with MPL and QS21 adjuvanted recombinant subunit vaccines
12. Modulation of the biological activity of bacterial endotoxin by incorporation into liposomes
13. A well-tolerated grass pollen specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A reduces allergic symptoms after only four preseasonal injections
14. Dermal toxicity
15. Pharmacologic myocardial preconditioning with monophosphoryl lipid A (MLA) reduces infarct size and stunning in dogs and rabbits
16. Liposomal malaria vaccine in humans: A safe and potent adjuvant strategy
17. Immune responses of systemic and mucosal lymphoid organs to Pru-Imune vaccine as a function of age and the efficacy of monophosphoryl lipid A as an adjuvant
18. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine
19. Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes
20. A comparison of the immunomedulating properties of two forms of menophosphoryl lipid A analogues
21. Induction of tumor necrosis factor, IFN-gamma and acute lethality in mice by toxic and non-toxic forms of lipid A
22. Induction of cell mediated immune responses in man with vaccines against Herpes simplex virus based on glycoprotein D
23. Immunogenicity and reactogenicity of a recombinant HSV-2 glycoprotein D vaccine with or without mono-phosphoryl lipid A in HSV seronegative and seropositlve subjects
24. Persistence of humoral and cellular immune response and booster effect following vaccination with Herpes simplex (gD2t) candidate vaccine with MPL
25. DNA vaccination of mice against rabies virus: Effects of the route of vaccination and the adjuvant monophosphoryl lipid A (MPL)
26. Enhancement of chemiluminescence and phagocytic activities by nontoxic and toxic forms of lipid A
27. Reversal of age-related deficient influenza virus-specific CTL responses and IFN-gamma production by monophosphoryl lipid A
28. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1
29. Distribution and localization of monophosphoryl lipid A in selected tissues of the rat
30. Modulation of humoral and cell-mediated immune responses by a structurally established nontoxic lipid A
31. Immunogenicity of liposomal malaria sporozoite antigen in monkeys: Adjuvant effects of aluminium hydroxide and non-pyrogenic liposomal lipid A
32. Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses
33. A novel adjuvant containing cell wall skeleton of mycobacteria and monophosphoryl lipid A substantially improves the immunogenicity in humans of a malaria vaccine
34. Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine
35. Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1
36. Comparison of intranasal and intramuscular immunization against human immunodeficiency virus type 1 with a DNA-monophosphoryl lipid A adjuvant vaccine
37. Evaluation of monophosphoryl lipid A (MPL) as an adjuvant: Enhancement of serum antibody response in mice to polysaccharide-protein conjugates by concurrent injection with MPL
38. Advances in vaccine adjuvants
39. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine
40. Adjuvant activity of non-ionic block co-polymers. V. Modulation of antibody isotype by lipopolysaccharides, lipid A and precursors
41. Immunogenicity of a recombinant hepatitis B vaccine with monophosphoryl lipid A administered following various two-dose schedules
42. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system
43. Enhanced immunogenicity of a recombinant genital warts vaccine adjuvanted with monophosphoryl lipid A
44. Mechanisms of non-specific resistance to microbial infections induced by trehalose dimycolate (TDM) and monophosphoryl lipid A (MPL)
45. Monophosphoryl lipid A as an adjuvant; Past experience and new directions
46. Safety, humoral and cellular immunity of a recombinant hepatitis B vaccine with monophosphoryl lipid A in healthy volunteers
47. Clinical development of a Herpes Simplex (gD2t) prophylactic vaccine
48. Humoral and cellular immune responses to three formulations of inactivated split influenza vaccine (ISIV) adjuvanted with QS-21
49. A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines